Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS).
Autoimmune lymphoproliferative syndrome (ALPS) is associated with mutations that impair the activity of lymphocyte apoptosis proteins, leading to chronic lymphadenopathy, hepatosplenomegaly, autoimmunity, and an increased risk of lymphoma. We investigated the utility of fluorodeoxyglucose positron emission tomography (FDG-PET) in discriminating benign from malignant lymphadenopathy in ALPS. We report that FDG avidity of benign lymph nodes in ALPS can be high and, hence, by itself does not imply presence of lymphoma; but FDG-PET can help guide the decision for selecting which of many enlarged nodes in ALPS patients to biopsy when lymphoma is suspected.
Rao
V Koneti
VK
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-1888, USA.
Carrasquillo
Jorge A
JA
Dale
Janet K
JK
Bacharach
Stephen L
SL
Whatley
Millie
M
Dugan
Faith
F
Tretler
Jean
J
Fleisher
Thomas
T
Puck
Jennifer M
JM
Wilson
Wyndham
W
Jaffe
Elaine S
ES
Avila
Nilo
N
Chen
Clara C
CC
Straus
Stephen E
SE
D001327:Autoimmune Diseases / Q000175:diagnosis / Q000473:pathology; D001706:Biopsy; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008206:Lymphatic Diseases / Q000175:diagnosis* / Q000473:pathology; D008223:Lymphoma / Q000175:diagnosis*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D008297:Male; D009154:Mutation; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D011446:Prospective Studies
D019788:Fluorodeoxyglucose F18